Navigation Links
Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
Date:7/17/2008

- Once-daily TMC278, the third anti-HIV compound to be developed in Tibotec

virology portfolio -

YARDLEY, Pa., July 17 /PRNewswire/ -- Tibotec Pharmaceuticals Ltd. announced today that two major phase III efficacy trials examining TMC278, its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in treatment-naive adults with HIV-1, are now recruiting patients. The global trials will compare the efficacy, safety and tolerability of TMC278 (25 mg) once daily oral tablet versus efavirenz (EFV), each coadministered with a background regimen of two nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs), in treatment-naive HIV-1-infected adults.

"Preliminary data have shown TMC278 to be active against HIV for patients who have not previously received treatment," Roger Pomerantz, MD, President of Tibotec Research and Development. "These phase III studies will provide important information on the safety and efficacy of this potential new treatment."

The first phase III, double-blind, randomized study, known as TMC278-C209 or ECHO (Efficacy Comparison in treatment-naive HIV-infected subjects Of TMC278 and EFV), will evaluate TMC278 (25 mg) once daily oral tablet versus EFV (600 mg) once daily, when combined with a fixed background regimen consisting of emtricitabine + tenofovir disoproxil fumarate. A second phase III, double-blind randomized study, known as TMC278-C215 or THRIVE (TMC278 against HIV, in a once daily RegImen Versus Efavirenz), will evaluate TMC278 (25 mg) once daily versus EFV (600 mg) once daily, when combined with an investigator-selected background regimen consisting of two N[t]RTIs (abacavir + lamivudine or tenofovir disoproxil fumarate + emtricitabine or zidovudine + lamivudine).

Each study will be conducted at more than 100 sites in over 20 countries, including the U.S., Canada and several countries in Latin America, among others, and will seek to enroll approximat
'/>"/>

SOURCE Tibotec Pharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
2. Maine Natural Health Company Conducts Dental Clinical Trial
3. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
4. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
5. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
6. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
7. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
8. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
9. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
10. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
11. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2008)...ir 11- and 12-year-olds from,meningitis, whooping ... ATLANTA, Aug 28 /PRNewswire-USNewswire/ -- The Ce...ational Center for Immunization and,Respiratory Di...ouncements,(PSAs) targeting the parents of pre-tee...he television and radio spots, part of CDC,s Pre-T...
(Date:8/27/2008)... Delaware, Montgomery,Philadelphia Counties, NOR...fter encouraging,results following the first night...ntal Protection will continue its efforts this eve...rne West Nile virus., Targeted aerial treatments ...n portions of Bucks, Delaware, Montgomery and Phil...
(Date:8/27/2008)...at The Children,s Hospital at, Montefiore Provid...and Specialty Services, ... Every Heart Condition, NEW YORK, Aug. 27 /PRNews...tefiore (CHAM) is bringing the medical miracle of ...owing the recent approval of its,transplant center...
(Date:8/26/2008)...fore Pharmaceuticals Inc.,presented data at the Se...,in Cancer in Washington, D.C., announcing the dis...hat demonstrate significant anticancer,activity in...lecular scaffold has been developed using,computat...kinase inhibitors,as well as isoform-selective sma...
Breaking Medicine Technology:DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 2DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 3Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 2Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 3Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 4Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3Respiratory illnesses and dog bites a concern for travelers to China for 2008 Olympics 24669 1Respiratory illnesses and dog bites a concern for travelers to China for 2008 Olympics 24669 2Geecf 3A Spectrum Blue Steel Announces Strategic Partnership with Al Manhal International Group of Abu Dhabi to Deploy Biosphere Facilities 6825 1Geecf 3A Spectrum Blue Steel Announces Strategic Partnership with Al Manhal International Group of Abu Dhabi to Deploy Biosphere Facilities 6825 2MTBC First Medical Billing Company in the U S To Offer Automated Real time Adjudication of Claims 24663 1MTBC First Medical Billing Company in the U S To Offer Automated Real time Adjudication of Claims 24663 2April Stewart Joins OrthoSynetics 28TM 29 as Corporate Communications Manager 24657 1
... Rexahn,Pharmaceuticals, Inc. (OTC BB:RXHN), a bio... development, and commercialization of,innovative ...rders,sexual dysfunction and other unmet medical ...ncipal Investigator of Phase I clinical,trial of t...n),will present results of the clinical study at ...
...n Transplantation, HORSHOLM, Denmark, May 31, 2007...ces positive Phase I clinical results for,its tran...nto US,Phase II clinical trials for organ transpla...nounces positive results,from its Phase I clinical...aily tacrolimus tablet. , A series of Phase I tria...
Other Medicine Technology:LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 2LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 3
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...sed on Monday, a drug that aims to prevent preterm...e earliest preterm births//, the main cause of dea...deza's (NASDAQ:ADZA) drug, Gestiva, is a long-acti...progesterone and is awaiting federal approval. ...
...rts have been restarted in India after declaring i... egg shipment to Muscat.// Due to the bird flu ou...ries around the world had stopped importing eggs f...t under control successfully by the several steps ...
...e of vaccination has yielded a much-improved quali...ing and help in fighting// many infectious disease...owever been slow and painstaking have been so bene...nd eradication of infectious diseases. It was unfo...
... balance in the body is skewed up is called Hypona... other conditions and requires urgent// treatment.... that some of the symptoms caused by hyponatremia ...a, vomiting, fatigue, and headache. Other serious ...
Other Medicine News:Health News:Gestiva – the pre-term birth drug probed by FD 2Health News:‘Bird flu-free’ India resumes egg expor 2Health News:Remarkable Progress In Development Of Vaccines 2Health News:Remarkable Progress In Development Of Vaccines 3Health News:Remarkable Progress In Development Of Vaccines 4
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
Medicine Products: